Last Updated: November 16, 2026

Details for Patent: 12,478,619

« Back to Dashboard


Which drugs does patent 12,478,619 protect, and when does it expire?

Patent 12,478,619 protects BYSANTI and is included in one NDA.

This patent has eight patent family members in eight countries.

Summary for Patent: 12,478,619
Title:Method of treatment with milsaperidone
Abstract:Described herein is an improved method of treatment with iloperidone or milsaperidone, of a patient in need of such treatment, comprising accounting for an increase in a serum urate level of the patient during treatment with the iloperidone or milsaperidone.
Inventor(s):Mihael H. Polymeropoulos
Assignee: Vanda Pharmaceuticals Inc
Application Number:US18/965,591
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 12,478,619

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Vanda Pharms Inc BYSANTI milsaperidone TABLET;ORAL 220358-001 Feb 20, 2026 RX Yes Yes ⤷  Start Trial ⤷  Start Trial METHOD FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN ADULTS BY REDUCING A POSSIBILITY OF AN ADVERSE CONSEQUENCE RESULTING FROM AN INCREASE IN A SERUM URATE LEVEL IN A PATIENT ⤷  Start Trial
Vanda Pharms Inc BYSANTI milsaperidone TABLET;ORAL 220358-001 Feb 20, 2026 RX Yes Yes ⤷  Start Trial ⤷  Start Trial METHOD FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY REDUCING A POSSIBILITY OF AN ADVERSE CONSEQUENCE RESULTING FROM AN INCREASE IN A SERUM URATE LEVEL IN A PATIENT ⤷  Start Trial
Vanda Pharms Inc BYSANTI milsaperidone TABLET;ORAL 220358-002 Feb 20, 2026 RX Yes No ⤷  Start Trial ⤷  Start Trial METHOD FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY REDUCING A POSSIBILITY OF AN ADVERSE CONSEQUENCE RESULTING FROM AN INCREASE IN A SERUM URATE LEVEL IN A PATIENT ⤷  Start Trial
Vanda Pharms Inc BYSANTI milsaperidone TABLET;ORAL 220358-002 Feb 20, 2026 RX Yes No ⤷  Start Trial ⤷  Start Trial METHOD FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN ADULTS BY REDUCING A POSSIBILITY OF AN ADVERSE CONSEQUENCE RESULTING FROM AN INCREASE IN A SERUM URATE LEVEL IN A PATIENT ⤷  Start Trial
Vanda Pharms Inc BYSANTI milsaperidone TABLET;ORAL 220358-003 Feb 20, 2026 RX Yes No ⤷  Start Trial ⤷  Start Trial METHOD FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY REDUCING A POSSIBILITY OF AN ADVERSE CONSEQUENCE RESULTING FROM AN INCREASE IN A SERUM URATE LEVEL IN A PATIENT ⤷  Start Trial
Vanda Pharms Inc BYSANTI milsaperidone TABLET;ORAL 220358-003 Feb 20, 2026 RX Yes No ⤷  Start Trial ⤷  Start Trial METHOD FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN ADULTS BY REDUCING A POSSIBILITY OF AN ADVERSE CONSEQUENCE RESULTING FROM AN INCREASE IN A SERUM URATE LEVEL IN A PATIENT ⤷  Start Trial
Vanda Pharms Inc BYSANTI milsaperidone TABLET;ORAL 220358-004 Feb 20, 2026 RX Yes No ⤷  Start Trial ⤷  Start Trial METHOD FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY REDUCING A POSSIBILITY OF AN ADVERSE CONSEQUENCE RESULTING FROM AN INCREASE IN A SERUM URATE LEVEL IN A PATIENT ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 12,478,619

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2024278999 ⤷  Start Trial
China 121218989 ⤷  Start Trial
European Patent Office 4687899 ⤷  Start Trial
Israel 324466 ⤷  Start Trial
Japan 2026519236 ⤷  Start Trial
South Korea 20260019503 ⤷  Start Trial
Mexico 2025014073 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.